BioMarin lays out its PhIII strategy for its closely-watched gene therapy for hemophilia A – Endpoints News
Endpoints News |
BioMarin lays out its PhIII strategy for its closely-watched gene therapy for hemophilia A
Endpoints News When it comes to gene therapy studies, anything other than a perfect score always raises a red flag about their future in late-stage testing. And nobody gets a perfect score. BioMarin was reminded of that lesson again today as it carefully laid out the … |
